All In Biotech

Drug Trial Radar · NCT06989983

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

An Open-Label, Two-Period Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

May 20, 2025

Primary completion

Jun 25, 2025

Study completion Jun 25, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Quotient Sciences
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to investigate how the body breaks down and gets rid of the test medicine, AZD5462. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14), which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

Conditions

  • Heart Failure

Interventions

  • AZD5462 film-coated tabletDrug

    Oral, fasted

  • [14C]AZD5462 Solution for InfusionDrug

    Intravenous, fasted

  • [14C]AZD5462 Oral SolutionDrug

    Oral, fasted

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount of AZD5462 excreted (Ae) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
  2. Amount of AZD5462 excreted expressed as a percentage of the dose administered (Fe) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
  3. Cumulative amount of AZD5462 excreted (CumAe) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
  4. Cumulative amount of AZD5462 excreted expressed as a percentage of the dose administered (CumFe) - Period 1Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
  5. Absolute bioavailability - Period 2Time frame: Plasma sample collection from pre-dose to 72 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ruddington, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.